Search hospitals > California > Fremont
Palo Alto Medical Foundation-Fremont
Claim this profileFremont, California 94538
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast Cancer
Conducts research for Recurrence
78 reported clinical trials
8 medical researchers
Summary
Palo Alto Medical Foundation-Fremont is a medical facility located in Fremont, California. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Recurrence and other specialties. Palo Alto Medical Foundation-Fremont is involved with conducting 78 clinical trials across 250 conditions. There are 8 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Edmund W. Tai.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Ari Baron, MDAlta Bates Summit Medical Center-Herrick Campus7 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
29 reported clinical trials
67 drugs studied
Deepti BehlCalifornia Pacific Medical Center-Pacific Campus4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
49 drugs studied
Kristie A. BobolisAlta Bates Summit Medical Center-Herrick Campus1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
27 drugs studied
Edmund W. TaiAlta Bates Summit Medical Center-Herrick Campus10 years of reported clinical research
Studies Cancer
Studies Lung Cancer
7 reported clinical trials
37 drugs studied
Clinical Trials running at Palo Alto Medical Foundation-Fremont
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Melanoma
Cancer
Multiple Myeloma
Ovarian Cancer
Fallopian Tube Cancer
Vulvar Cancer
Peritoneal Cancer
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Palo Alto Medical Foundation-Fremont?
Palo Alto Medical Foundation-Fremont is a medical facility located in Fremont, California. This center is recognized for care of Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Recurrence and other specialties. Palo Alto Medical Foundation-Fremont is involved with conducting 78 clinical trials across 250 conditions. There are 8 research doctors associated with this hospital, such as Ari Baron, MD, Deepti Behl, Kristie A. Bobolis, and Edmund W. Tai.